Abbvie completes acquisition of Allergan

The completion of Abbvie’s acquisition of Allergan is set to create leadership positions for the company in potential therapeutic segments including Immunology, Hematologic Oncology, Neuroscience, and Allergan Aesthetics.
Abbvie is set to expand its revenue base through recently launched drugs in Immunology, with Humira, Skyrizi and Rinvoq. In Hematologic Oncology, the company launched Imbruvica and Venclexta. On the other hand, the acquisition enables the emerging entity to gain from Botox Therapeutics, Vraylar and Ubrelvy in Neuroscience and Botox and Juvederm in aesthetics business.
Under the terms of the transaction agreement, Allergan shareholders will receive 0.8660 AbbVie shares and $120.30 in cash for each Allergan share, for a total consideration of $193.23 per Allergan share (based on the closing price of AbbVie’s common stock of $84.22 on May 7, 2020)